Review Article
Intervertebral Disc Stem/Progenitor Cells: A Promising “Seed” for Intervertebral Disc Regeneration

Yuxiang Du,1 Zhikun Wang,1 Yangming Wu,2 Chengyi Liu, and Lingli Zhang

1School of Kinesiology, Shanghai University of Sport, Shanghai 200438, China
2School of Physical Education & Sports Science, South China Normal University, Guangzhou, 510631 Guangdong, China

Correspondence should be addressed to Chengyi Liu; liutcy@scnu.edu.cn and Lingli Zhang; lingliwdc@163.com

Received 10 May 2021; Accepted 8 July 2021; Published 29 July 2021

Copyright © 2021 Yuxiang Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Intervertebral disc (IVD) degeneration is considered to be the primary reason for low back pain (LBP), which has become more prevalent from 21 century, causing an enormous economic burden for society. However, in spite of remarkable improvements in the basic research of IVD degeneration (IVDD), the effects of clinical treatments of IVDD are still leaving much to be desired. Accumulating evidence has proposed the existence of endogenous stem/progenitor cells in the IVD that possess the ability of proliferation and differentiation. However, few studies have reported the biological properties and potential application of IVD progenitor cells in detail. Even so, these stem/progenitor cells have been consumed as a promising cell source for the regeneration of damaged IVD. In this review, we will first introduce IVD, describe its physiology and stem/progenitor cell niche, and characterize IVDSPCs between homeostasis and IVD degeneration. We will then summarize recent studies on endogenous IVDSPC-based IVD regeneration and exogenous cell-based therapy for IVDD. Finally, we will discuss the potential applications and future developments of IVDSPC-based repair of IVD degeneration.

1. Introduction

Low back pain (LBP) is the most common musculoskeletal system disease, affecting 80% of the population. In addition to pain, LBP restricts physical activity and can lead to disabilities. Additionally, it causes a major socioeconomic burden [1–4]. Clinically, LBP always positively correlates with the degeneration of the intervertebral disc (IVD) [2, 5]. The IVD is a fibrocartilaginous tissue located between two adjacent vertebral bodies, which is a complex tissue composed of three distinct components: the nucleus pulposus (NP), the anulus fibrosus (AF), and the cartilage endplates (CEP) [6, 7]. The unique structural organization of IVD is important for spine movements, which exhibit mechanical properties such as high compressive and tensile strength and contribute to the bipedalism in humans [8, 9].

With aging, the IVD undergoes a degenerative process, known as intervertebral disc degeneration (IVDD), through cell death, extracellular matrix dehydration, and disorganization. The result of IVDD is the loss of the shock-absorbing properties of the spine [10–12]. This natural aging process can be accelerated or amplified by the accidental trauma, sedentarrayness, or high mechanical load [11]; however, the pathogenic mechanism of IVDD is not fully understood.

Conventional treatments of IVDD or LBP almost include conservative physical therapy, sealing therapy, and surgical treatment [13, 14]. These treatments majorly focused on relieving pain or inflammation and do not fundamentally cure the disease. Therefore, the development of new treatment strategies for IVDD is critical.

Since the 21st century, the cell-based transplantation therapy and tissue bioengineering have been used for tissue regeneration and have become a potential treatment for IVDD. In animal studies, cell transplantation therapy has been found to be effective for IVDD, using nucleus pulposus cells (NPCs), bone marrow mesenchymal stem cells (BMSCs), olfactory-derived mesenchymal stem cells (OMSCs), adipose mesenchymal stem cells (AMSCs), and induced pluripotent as cell transplantation “seeds” [15–19]. However, cell-based therapy for IVDD is limited due to the harsh environment of the intervertebral disc [19–21]. The intervertebral disc is high in osmolarity, subject to excessive
mechanical loading, deficient in nutrition, low in oxygen tension, and acidic, all of which can impair the viability, proliferation, and differentiation of transplanted cells [21, 22]. Therefore, environmentally compatible cell sources are required for IVD regeneration.

Emerging evidence shows that there are endogenous stem/progenitor cells in the IVD (IVDSPCs) [23–26] that can differentiate into NPCs and reconstruct the function and construction of degenerated intervertebral discs. These properties can be an effective strategy for IVDD treatment. In this review, we will first introduce IVD, describe its physiology and stem/progenitor cell niche, and characterize IVDSPCs between homeostasis and IVD degeneration. We will then summarize recent studies on endogenous IVDSPC-based IVD regeneration and exogenous cell-based therapy for IVDD. Finally, we will discuss the potential applications and future developments of IVDSPC-based repair of IVD degeneration.

2. IVD Progenitor Cells in Disc Homeostasis

2.1. The Niche for Progenitor Cells in IVD. The IVD is important for maintaining the stability of the spine by distributing mechanical loads and absorbing the mechanical shock produced during movement [27]. Each IVD is composed of three distinct regions that ensure a unique structure: the gelatinous and hydrated nucleus pulposus (NP) at the center of the IVD, the annulus fibrosus (AF) surrounding the NP at the IVD periphery, and cartilage endplates (CEPs) above and below the IVD between adjacent vertebrae [28]. Each region represents a structural and biological entity that participates in disc homeostasis (Figure 1).

NPs are randomly organized gelatinous tissue that contain two major types of cells: notochordal cells, which are large vacuolated cells from the embryonic notochord, and nucleopulpocytes, which are small spherical chondrocyte-like cells [11, 29, 30]. In healthy IVD, nucleopulpocytes have strong anabolic activity to synthesize abundant extracellular matrix proteins. These extracellular matrix proteins are rich in aggrecan, type II collagen, and hyaluronic acid. Aggrecan is composed of negatively charged sulfated glycosaminoglycans, making aggrecan hydrophilic. Hyaluronic acid retains water and contributes to the osmotic pressure that maintains the mechanical bearing capacity of the NPs and the vertebral disc height [31–33].

AFs are fibrocartilaginous rings composed essentially of collagen type I fibers. These fibers are radially oriented in opposite directions throughout concentric lamellae and are associated with an interlamellar matrix consisting of type II collagen, proteoglycans, and elastin [7, 28]. The AF is divided into two compartments: the outer AF, which is mainly composed of organized type I collagen fibers with high elastic and compressive properties, and the inner AF, which is a transitional area between the outer AF and the NP, which is less organized [34, 35].

CEPs interface with the adjacent vertebral bodies. CEPs are composed of hyaline cartilage cells and chondrocytes, which can synthesize abundant type II collagens and proteoglycans [11, 36]. Similar to the articular cartilage, the IVD is the most avascular tissue in the human body [28]. Although disc cells are accustomed to survive in a nutrient-deficient and hypoxia environment on the evolution, enough oxygen and glucose are necessary for disc cells for their growth and functional maintenance, which relies on the important diffusion ability of the CEPs [37, 38].

Stem cell niches are specific anatomical regions where stem cells reside in a quiescent state. Emerging evidences have been found of IVDP stem/progenitor cells and stem cell niches in IVD. However, as described above, the IVD is comprised by three distinct components: the central gelatinous NP, the outer AF, and the upper and lower CEP. Thus, due to the distinct anatomical regions of IVD, the IVDSPCs are usually divided into three subsets by recent studies, respectively, nuclei pulposus-derived progenitor cells (NPSPCs), annulus fibrosus-derived progenitor cells (AFSPCs), and cartilage endplate-derived progenitor cells (CESPCs).

Risbud et al. [39] firstly identified a population of cells in the AF region of human IVD that expresses the surface markers of stem cells and have the trilineage differentiation ability (adipogenic, osteogenic, and chondrogenic differentiation). However, the detailed presence of a stem cell niche in the IVD is firstly described by Henriksson et al. [40, 41]. In their study, they detected cell proliferation zones by in vivo 5-bromo-2-deoxyuridine (BrdU) labeling in rabbits. They proposed that IVD stem cell niches might exist in the AF border to ligament zone and the perichondrium region adjacent to the epiphyseal plate has been suggested to be the IVDSPC niche.

Sakai et al. [23] firstly identified populations of NP progenitor cells that are Tie2 positive (Tie2+) and disialoganglioside 2 positive (GD2+) in mice and humans. They claimed that these NPSPCs can form spheroid-like colonies that express type II collagen and aggrecan. Besides, these cells could differentiate into mesenchymal lineages and induced...
reorganization of nucleus pulposus tissue. In the other study, Erwin et al. [42] also demonstrated that NPSPCs are present within the NP region, express genes classic for mesenchymal stem cells, and can differentiate into multiple cell lineages in vitro. In recent years, many studies have reported the existence of NPSPCs in various animal models; these cells are believed to have the ability to contribute to the cellular organization in the IVD.

Furthermore, the results from Kim et al. illustrated that rabbit notochordal cells could stimulate the migration of cells from the CEP into the NP region and changed a notochordal NP into a fibrocartilaginous NP [43, 44]. In 2011, Liu et al. successfully isolated a universal cell population with stem cell characteristics from human CEPs, which are superior in terms of the osteogenic and chondrogenic capacity in vitro [45]. Besides, Xiong et al. [46] also isolated and identified a population of CEPSCs, which could migrate from CEP to NP tissue, and this migration could be inhibited by macrophage migration inhibitory factor.

The discovery of CEPSCs is important for the future of IVDD cell-based therapy. Current cell-based therapies mainly target NP and AF degeneration, but calcification of the CEP can affect IVDD regeneration. CEP calcification can block nutrient supply to the endogenous or implanted cells and impair the cell regeneration process.

Recently, some researchers proposed that the stem cell niche in the IVD is a dynamic microenvironment consisting of the unique extracellular matrix (ECM) and neighboring cells that can regulate local stem/progenitor cells [41, 47]. In other words, despite the different locations of stem/progenitor cells in the different regions in IVD, the AFSPCs, NPSPCs, and CESPCs may contain the same population of stem/progenitor cells which have the same origin and biological characteristics. In brief, from these studies, we can define the existence of endogenous IVDSPCs in different regions both in an animal model and in human IVD.

### 2.2. Properties of IVD Progenitor Cells

Previous studies have already showed that IVDSPCs have many similar surface markers with marrow mesenchymal stem cells (MSCs) [48], which express CD73, CD90, and CD105 but not CD34, CD45, CD14, CD11b, CD79, CD19, and HLA-DR. The current characterization and related study findings of IVD progenitor cell characteristics are described in Table 1. Besides, IVDSPCs may also express markers known to be expressed by other types of stem/progenitor cells. For instance, clonal cells isolated from nonchondrodystrophic canine NP cells expressed the pluripotent stem cell marker genes SOX2, OCT3/4, and NANOG [42, 49]. According to the studies, a small proportion of human IVDSPCs also express CD133 [39, 50], a surface glycoprotein usually expressed on many types of stem cells and cancer stem cells [51, 52]. A minor population of human NP cells from degenerated IVDs also express CD34 [53], which is a marker for haematopoietic stem cells and some progenitor cells. Notably, previous studies have shown that IVD cells, such as NPs and AFs, also express surface markers similar to mesenchymal stem cells, making it harder to distinguish the IVDSPCs from other IVD cells [23]. Therefore, it is necessary to explore the distinct surface markers of IVDSPCs. For instance, Sakai and his group [23] have also indicated that the tyrosine kinase endothelial receptor (Tie2) and disialoganglioside 2 (GD2) are sensitive markers of NPSPCs. Besides, with the development of single-cell sequencing technology, it has already been a powerful tool to identify new clusters of stem/progenitor cells in other tissues, which can help to clearly classify subpopulations of all IVD cells.

In addition to surface marker expression, MSCs also should be plastic adherent and be able to undergo osteogenesis, adipogenesis, and chondrogenesis, as defined by the International Society for Cellular Therapy. In this respect, IVDSPCs also have compared properties with MSCs. For example, CESPCs are reported to have a similar proliferation rate but a better osteogenic and chondrogenic ability compared to BMSCs [45]. In a rat model, Zhang et al. [54] reported that NPSPCs have a similar proliferative capacity with BMSCs. However, Wu et al. [55] found that NPSPCs were expressed less than MSC surface markers and exhibited reduced proliferation capability and differentiation potentials than umbilical cord-derived MSCs [55]. What is more, in the continuous studies of Chen et al. [56, 57], they reported that NPSPCs have a greater viability, proliferation rate, and ECM metabolism than ASCs under hypoxic conditions or acidic conditions. By the way, many studies have shown that hypoxic conditions promote differentiation in MSCs into NP-like cells [58–60]. Besides, Liang et al. [61] compared the biological characteristics of NPSPCs, AFSPCs, and CESPCs from human IVD. They concluded that the cell morphology of these three kinds of IVDSPCs was not significantly different. However, in vitro proliferation and differentiation assay demonstrated that AFSPCs had the best stem-cell-like characteristics. However, Wang et al. [62] reported that there was no significant difference in proliferation ability among NPSPCs, AFSPCs, and CESPCs and claimed that CESPCs have the strongest osteogenic and chondrogenic potentials compared to NPSPCs and AFSPCs.

Although intervertebral discs have been characterized, these studies are predominantly in vitro, which may be different in vivo. Discrepancies that exist between studies may be explained in part by the different species or cell isolation and culturing protocols. Thus, future studies should focus on identifying IVDSPC properties in vivo by fluorescent-labeled animal models and explore the localization of the IVDSPCs in the IVD development by lineage tracing or fate mapping.

### 3. IVD Progenitor Cells in DISC Degeneration

IVDD is a progressive disease caused by genetics, aging, and injuries that leads to molecular, cellular, structural, and mechanical changes of the IVD [63–66]. As degeneration occurs, loss of proteoglycans and hydration in NP affects homeostasis in the ECM, mechanical properties, and shock absorber function. As such, mechanical force should be distributed evenly over the IVD because it can increase in the tensile forces exerted on the AF and accelerate degeneration. A protruding NP would crush the AF, leading to the compression of the adjacent sensory nerve and subsequently
cause LBP [67, 68]. As IVDD progresses, increased secretion of inflammatory factors and other catabolic factors promote blood vessels and sensory nerves to grow into NP and AF region and amplify pain through a degenerative cascade [63, 67]. The IVD relies on CEP to exchange nutrients and metabolites. However, the CEP is gradually calcified during IVDD. This calcification impedes nutrient diffusion and metabolite releases, resulting in an acidic and nutritionally deficient environment for IVDSPCs [11, 69].

Similar to many endogenous progenitor cells, IVDSPCs can also maintain a dynamic balance between healthy IVD and degenerated IVD [22, 24]. Several studies have reported the changes of IVDSPC as IVD degenerated (Figure 2). Hypoxia, acidic, high mechanical loading, and inflammatory environment in degenerative IVD can result in reduced number and migration ability of IVDSPCs. For example, hypoxia can inhibit the viability and proliferation of NPSCs but promote the chondrocytic differentiation of NPSCs [65]. Mizrahi et al. [70] compared NPSC function from healthy and degenerated porcine discs and found that NP cells from degenerate discs have superior proliferation ability in vitro. Liu et al. [71] reported that acidic conditions could significantly inhibit cell proliferation and increase cell apoptosis of IVDSPCs. The acidic microenvironment in degenerated IVD can also inhibit the viability and proliferation ability of the IVDSPCs, as well as the reduction of aggrecan, collagen II, and metalloproteinase-3 and the increase of matrix metalloproteinase-2 and thrombospondin motifs-4 expression in NPSCs [57]. Besides, as degeneration occurred, the increased mechanical stress including compression loading and various kinds of stress may significantly affect IVDSPCs [72, 73]. For example, Deng et al. [74] reported that continuous stress could affect endogenous IVDSPC migration. Liang et al. [75] also found that the increased compressive loading could inhibit the viability differentiation, colony formation, and migration ability of IVDSPCs and downregulate the expression of stem cell-related genes. What is more, inflammation in degenerated IVD can also impact IVDSPCs [76, 77] by increasing IL-1β and inhibiting the proliferation and anabolism of IVDSPCs [78]. Overall, these studies show the

Table 1: Identification and surface markers of IVDSPCs.

| Species          | Cell type   | Surface markers                                      | References                      |
|------------------|-------------|------------------------------------------------------|---------------------------------|
| Human            | NPSPCs      | CD73+, CD90+, CD105+, CD29-CD45-                     | Qi et al., 2019 [115]           |
| Human            | NPSPCs      | CD73+, CD90+, CD105+, CD34+, CD45-, HLA-DR-          | Liu et al., 2017 [71]           |
| Human            | NPSPCs      | CD73+, CD90+, CD105+, CD34+, CD45-                   | Chen et al., 2016 [116]         |
| Human            | NPSPCs      | Tie2+, GD2+, Flt1+, CD271+, CD24-                    | Sakai et al., 2012 [23]         |
| Human            | NPSPCs      | CD90+, CD73+, CD105+, CD106+, CD166+, CD14-, CD19-, CD24-, CD34-, CD45-, HLA-DR- | Blanco et al., 2010 [117] |
| Human            | NPSPCs      | CD29+, CD44+, CD105+, CD14-, CD34-, CD45-, HLA-DR-  | Shen et al., 2015 [25]          |
| Human            | NPSPCs      | Tie2+, GD2+, Nanog+, Oct-4+, Sox-2+                   | Li et al., 2017 [118]           |
| Rat              | NPSPCs      | CD73+, CD90+, CD105+, CD34-, CD45-                   | Zhao et al., 2017 [119]         |
| Canine           | NPSPCs      | CD133+, Ki67+, Nanog+, NCAM+, Nestin+, Oct3/4+, Sox2+, Brachyury- | Erwin et al., 2013 [42] |
| Human            | NPSPCs      | CD49a+, CD63+, CD73+, CD90+, CD105+, CD166+, p75 NTR+, CD133/1+, CD34- | Risbud et al., 2007 [39] |
| Human, rat, rabbit | AFSPCs    | PCNA+, CD166+, C-kit+, Jagged1+, Notch1+            | Henriksson et al., 2009 [40]    |
| Human, rat, rabbit | AFSPCs    | Notch1+, Delta4+, CD117+, STRO-1+, C-kit low, Ki67 low | Henriksson et al., 2012 [41]    |
| Human            | AFSPCs      | CD29+, CD49c+, CD51+, CD73+, CD90+, CD105+, CD166+, CD184+, CD24+, Sox-1+, Nestin+, NSE+, CD31-, CD34-, CD45-, CD106-, CD117-, CD133- | Feng et al., 2010 [122] |
| Human            | AFSPCs      | CD14+, CD29+, CD44+, CD73+, CD90+, CD105+, STRO-1+, CD34-, CD45- | Gruber et al., 2016 [123] |
| Rabbit           | AFSPCs      | CD29+, CD44+, CD166+, Oct4+, Nucleostemin+, SSEA-4+, CD4+, CD8-, CD14- | Guo et al., 2018 [124] |
| Rabbit           | AFSPCs      | CD29+, CD44+, CD166+, Oct4+, SSEA-4+, CD4+, CD8-, CD14- | Liu et al., 2014 [125] |
| Human            | CEPSCs      | CD73+, CD90+, CD105+, CD34+, CD45-, HLA-DR-         | Yuan et al., 2018 [126]         |
| Human            | CEPSCs      | CD44+, CD73+, CD90+, CD105+, CD133+, CD166+, Stro-1+, CD14-, CD19-, CD34-, CD45-, HLA-DR- | Yao et al., 2016 [127] |
| Human            | CEPSCs      | CD44+, CD73+, CD90+, CD105+, CD133+, CD166+, Stro-1+, CD14-, CD19-, CD34-, CD45-, HLA-DR- | Liu et al., 2011 [45] |
| Human            | CEPSCs      | CD44+, CD73+, CD90+, CD105+, CD133+, CD166+, Stro-1+, CD14-, CD19-, CD34-, CD45-, HLA-DR- | Huang et al., 2012 [50] |
IVDSPCs is promising for IVDD. Improving the microenvironment to activate endogenous IVDSPCs in degenerated IVDs is crucial for IVDD. Current treatments do not address the fundamental problems of IVDD, such as the degenerated disc dysfunction and structure disorder structure. With the growing interest in cell transplantation for tissue regeneration and a better understanding of the IVDD pathophysiology, cell-based therapy is a potential treatment for IVDD. Cell-based therapies are expected to restore the biomechanical functions of the IVD, as well as the acidic, hypoxic, and nutrient-deficient microenvironment. Therefore, it is imperative that the cell “seed” for cell-based therapy should have the strong ability of survival, proliferation, and differentiation and the ability to rebuild a comparable microenvironment of the IVD.

In the early 21st century, MSCs were one of the most used cell populations for regeneration. MSCs, such as BMSCs, OMSCs, and AMSCs, can differentiate into NP-like cells in vitro [79, 80] and restore radiographically assessed IVD height in animal models, which might be an effective strategy for the treatment of IVDD. BMSCs and AMSCs are commonly used as cell-transplant seeds due to their accessibility and excellent differentiation abilities and have been found to be effective for improving degenerated IVD. Hussain et al. [81] delivered BMSC-seeded high-density collagen into injured IVDs of sheep. Within six weeks, the disc high index improved, which indicated a good repair of the IVD. Noriega et al. [82] transplanted BMSCs into degenerated IVDs of LBP patients by intradiscal injection. Clinical outcomes were followed for 1 year and included evaluation of pain, disability, and quality of life. The BMSC-treated patients displayed quick and significant improvement in algofunctional indices compared to the healthy controls. Wang et al. [16] preconditioned BMSCs in hypoxia before transplantation and saw enhanced cell survival in degenerated rat IVD.

4. IVD Progenitor Cells in DISC Regeneration

4.1. Traditional Cell-Based Therapy. Current treatments do not target the fundamental problems of IVDD, such as the degenerated disc dysfunction and structure disorder structure. With the growing interest in cell transplantation for tissue regeneration and a better understanding of the IVDD pathophysiology, cell-based therapy is a potential treatment for IVDD. Cell-based therapies are expected to restore the biomechanical functions of the IVD, as well as the acidic, hypoxic, and nutrient-deficient microenvironment. Therefore, it is imperative that the cell “seed” for cell-based therapy should have the strong ability of survival, proliferation, and differentiation and the ability to rebuild a comparable microenvironment of the IVD.

In the early 21st century, MSCs were one of the most used cell populations for regeneration. MSCs, such as BMSCs, OMSCs, and AMSCs, can differentiate into NP-like cells in vitro [79, 80] and restore radiographically assessed IVD height in animal models, which might be an effective strategy for the treatment of IVDD.

BMSCs and AMSCs are commonly used as cell-transplant seeds due to their accessibility and excellent differentiation abilities and have been found to be effective for improving degenerated IVD. Hussain et al. [81] delivered BMSC-seeded high-density collagen into injured IVDs of sheep. Within six weeks, the disc high index improved, which indicated a good repair of the IVD. Noriega et al. [82] transplanted BMSCs into degenerated IVDs of LBP patients by intradiscal injection. Clinical outcomes were followed for 1 year and included evaluation of pain, disability, and quality of life. The BMSC-treated patients displayed quick and significant improvement in algofunctional indices compared to the healthy controls. Wang et al. [16] preconditioned BMSCs in hypoxia before transplantation and saw enhanced cell survival in degenerated rat IVD. Elabd et al. [83] also demonstrated clinical safety and feasibility of the clinical use of hypoxic pretreated BMSCs for the treatment of IVDD in five patients. Magnetic resonance imaging (MRI) showed no abnormalities surrounding the treated region, and all patients self-reported overall improvement of LBP. Thus, pretreated MSCs before transplantation provided a new way to improve the effects of BMSC-based transplantation in IVDD. Moreover, Ishiguro et al. [84] developed an AMSC-based scaffold-free tissue-engineered construct as a novel cell therapy system for IVDD. The AMSC-based implantation system restored the IVD integrity and the biomechanical function in a rat tail model without destruction of surrounding vertebral structures. Recently, Muttigi et al. [85] optimized the matrilin-3 priming dose, duration, and culture conditions for the preparation of AMSC spheroids. They found that this system could enhance the secretion of growth factors to induce repair and restored and rehydrated the IVD microenvironment.

Besides, induced pluripotent stem cells (iPSCs) are another good choice for cell-based therapy for IVDD. Setton et al. [86, 87] promote iPSC differentiation into NP-like cells in vitro and provide a cell source for the development of new therapies for IVD diseases. However, they do not demonstrate the treatment efficacy of iPSC-derived NPs for IVD regeneration in animal models. Recently, Zhang et al. [88] reported that notochord-like and NP-like cells can be derived from human pluripotent stem cells using a compound-defined protocol. These iPSC-derived NP-like cells share high similarities with adolescent NP cells and attenuate injury-induced intervertebral disc degeneration after transplantation.

4.2. IVDSPC-Based IVD Endogenous Regeneration. Although exogenous MSC-based therapy is a promising treatment for IVDD, however, successful implementation of exogenous cell-based therapy is challenged by the specialized.
microenvironment of the IVD. Even in the steady state, the IVD is avascular, hypoxic, nutritionally deficient, and high biomechanical loading, which is hard to survive for exogenous cells. Unfortunately, all of these bad conditions would be exacerbated when IVDD occurred as described above, which seriously hindered the application of exogenous stem/progenitor cell-based treatment for IVDD. Furthermore, due to the uncontrollability of proliferation and differentiation of exogenous stem/progenitor cells in vivo, their clinical utility is also hampered by their osteogenic and tumorigenic potential [89]. Therefore, environmentally compatible cell sources, such IVDSPCs, are required.

When tissue is damaged, the inflammatory cells would quickly move to the injury site and release various kinds of cytokines to recruit endogenous stem/progenitor cells. Then, the recruited endogenous stem/progenitor cells undergo proliferation and differentiation to begin tissue regeneration. In recent years, many studies confirmed that endogenous stem/progenitor cells are an important source for tissue self-regeneration in many tissues, especially in the musculoskeletal system. For example, Lee et al. [90] identified a rare population of CD146+ tendon progenitor cells, which exhibited clonogenic capacity and multilineage differentiation ability. They also demonstrated that the CD146+ tendon progenitor cells could contribute to the regeneration after tendon injury. Using a biodegradable material combined with Glil+ endogenous suture MSCs, Yu et al. [91] successfully regenerated a functional cranial suture that corrects skull deformity, normalizes intracranial pressure, and rescues neurocognitive behavior deficits in Twist1+/− mice with craniosynostosis. All these studies indicate the great potential of endogenous stem/progenitor cells for injury regeneration in the skeletal system.

While endogenous repair is also present in the IVD [22], injury to the IVD affects the repair process by stem/progenitor cells. The reason for the failure of IVD endogenous repair is likely due to the insufficient endogenous progenitor cell recruitment to the damaged site and the adverse IVD microenvironment affecting the activity and viability of IVD progenitor cells [22]. Therefore, recruiting enough IVDSPCs and reforming the adverse microenvironment in the degenerated IVD must be a primary strategy for the endogenous repair of IVDD. For instance, Pattappa et al. [92] reported that CCL5 is a key chemoattractant that is produced and released by the intervertebral disc cells. Therefore, these factors enhance stem/progenitor cell mobilization in regenerative therapies for early stages of disc degeneration. Ying et al. [93] also found that stromal cell-derived factor-1α (SDF-1α) released in the degenerated IVD can activate and recruit endogenous NPSPCs. They suggested that SDF-1α is important for in situ IVDD regeneration.

Utilizing chemokines to recruit endogenous or exogenous progenitor cells is a promising strategy for improving endogenous IVD regeneration, especially when combined with compatible biomaterials. Pereira et al. [94] used hyaluronan-poly(N-isopropylacrylamide) hydrogel as a chemoattractant delivery system to slow-release SDF-1 when transplanted into the degenerated IVD. This system could enhance both the number of recruited IVDSPCs and their migration distance in the IVD. Notably, Frapin and colleagues [95] developed a new delivery system composed of pullulan microbeads that deliver CCL5 to promote recruitment of IVDSPCs, as well as TGF-β1 and GDF-5 synergistic cocktail to stimulate the synthesis of an NP-like ECM synthesis. This strategy promoted endogenous repair of IVD. In another respect, the degenerated IVD environment is hypoxic, acidic, inflammatory, and high mechanical loading as described above, which results in reduced mobilization of IVDSPCs. Therefore, overcoming the adverse microenvironment in the IVD to promote endogenous repair is a promising strategy as well. For example, Liu et al. [96] reported that the antioxidative and anti-inflammatory properties of aspirin significantly improve IVDD. Zhang et al. [97] also demonstrated that melatonin could modulate ECM remodeling and attenuate the IVDD in a rat tail puncture model by resisting the inflammatory cytokines. Using inhibiting an acid-sensing ion channel can reduce the adverse effects of an acidic environment on NPSPCs by allowing an extracellular receptor to maintain function in an acidic environment [71]. These studies demonstrate that improving the microenvironment for cell-based therapy can improve outcomes.

4.3. Future IVDSPC-Based Therapy for IVD Regeneration.

Despite the advantages of IVDSPCs for disc regeneration, there are some limitations to the clinical application of IVDSPC-based transplantation therapy for IVD regeneration. First, current understanding of IVDSPCs is insufficient, hampering the discovery of new IVDSPCs and even the development of IVDSPC-based therapy for IVDD. As single-cell sequencing technology develops, we need to understand the role of heterogeneous cell populations in the NPs, AFs, and even CEPs for IVDSPCs. Wang et al. [98] used the Sc-RNA sequencing technology to divide the disc cells into five categories at the single-cell level. Among the five groups, they identified a population of cells (Eng+ and Mcam+) with a stem cell-like phenotype by tracking common MSC marker genes. Although they did not demonstrate the proliferation and differentiation ability of these cells, this study paved the way for further research on the clarification of subpopulations of disc cells by Sc-RNA sequencing technology, which could further contribute to the discovery of a powerful cell “seed” for cell-based therapy for IVDD.

Second, more appropriate and compatible materials need to be designed to serve as a more suitable carrier for IVDSPCs. Compared to the normal liquid carrier, biomaterials can avoid the cell leakage from the pinhole of the intervertebral space and provide a suitable environment for cell “seeds.” These properties can enhance the curative effect of cell-based therapy. There are mainly two types of biomaterials for intervertebral disk regeneration: biomaterials with high mechanical strength and biomaterials with certain elasticity and softness. Isa and colleagues [99] found that HA hydrogel alleviated the pain in a rat disc injury model. This study suggests that HA hydrogel may have an injectable carrier for IVDSPCs that could be translated to degenerated disc. Chen et al. [100] developed a multifunctional polyethylene glycol hydrogel with injectable and self-healing
properties. They also loaded a small molecule drug, Ago-mir874, into this system to mimic miRNA874 by downregulating the expression of matrix metalloproteinases in the NP and restoring the extracellular microenvironment. To some extent, some growth factors that benefit for IVDSPCs’ proliferation or vitality could be added in the biomaterial for disc regeneration ref. Despite the great potential of biomaterials for cell therapy, some problems remained. Sometimes, these materials may induce CEP damage because of their high mechanical strength. Contrastingly, biomaterials that are too soft can break into fragments because of the high mechanical load of IVD. Therefore, biomaterials with appropriate elasticity and stiffness should be developed for delivering IVDSPCs into the IVD and growth factors could be used to improve the microenvironment for transplanted IVDSPCs.

Finally, although cell-based therapy might be an effective approach for the treatment of IVDD, many obstacles remained [21, 89]. For example, Gianluca et al. [89] reported that transplanted cells could form osteophyte and might migrate out of the IVD. The uncontrollable proliferation of transplanted cells also hampered the clinical utility of cell-based therapy because of tumorigenic potential [89, 101]. What is more, the cell-based therapy for IVDD requires a large number of injected cells (usually ~10^7) [20]. Although IVDSPCs can perform as a good cell resource for the cell therapy of IVDD, the difficult collection and insufficient number of endogenous IVDSPCs may hamper the clinical utility of IVDSPCs. Therefore, there has been a shift toward cell-free therapies for IVDD to circumvent the aforementioned obstacles [102–104]. Extracellular vesicles (EVs) are lipid membrane particles carrying proteins, lipids, DNA, and various types of RNA that are involved in intercellular communication. EVs derived from stem/progenitor cells have been suggested to be excellent therapeutic agents in many diseases, including IVDD [105–108]. Many different groups have demonstrated that MSC-derived EVs can inhibit apoptosis and promote the proliferation of the IVD cells. For example, Cheng et al. [109] reported that BMSC-derived EVs can inhibit NP cell apoptosis and reduce IVDD through miR-21. Xiang et al. [110] and Liao et al. [111], respectively, demonstrated that MSC-derived EVs can attenuate ER stress-induced NP cell apoptosis and retarded IDD progression in a rat model. Besides, Hingert et al. [112] treated human degenerated disc cells with MSC-derived EVs in vitro and saw more than a 50% increase in cell proliferation and a decrease in apoptosis. Recently, Guo et al. [113] reported that MSC-derived EVs can promote NP cell proliferation. They found that matrilin-3, an extracellular matrix protein, is enriched in EVs and is necessary for EVs to promote the proliferation of NP cells. In addition to affecting cell proliferation and apoptosis, EVs can also play an important role in metabolic programming of disc cells. For an instance, Li et al. [114] found that MSC-derived EVs can reduce ECM degradation by downregulating matrix-degrading enzymes and promote the anabolism of collagen II and aggrecan, protecting NP cells from acidic pH-induced apoptosis. Guo et al. [113] also found that MSC-derived EVs can promote ECM synthesis of NP cells. These studies suggested that MSC-derived EVs exert a protective effect on disc cells by attenuating the pathological environment in IVD. However, there are few reports about the influences by using IVDSPC-derived EVs to treat degenerated disc cells. In view of the better biocompatibility of IVDSPCs in the harsh IVD environment than exogenous MSCs, IVDSPC-derived EVs may have an excellent effect in protecting disc cells from degeneration and contribute to the regeneration of the IVD.

5. Conclusion

IVDD is a primary reason for LBP, causing an enormous economic and medical burden due to the inadequate efficacy of traditional clinical therapy. The discovery of IVD endogenous stem/progenitor cells brings new insight for IVDD treatment, which might be an excellent cell “seed” for IVDD regeneration. The IVDSPCs are like MSCs in surface markers, proliferation, and differentiation, with the added benefit of being able to withstand the harsh microenvironment of degenerated IVD. These properties allow IVDSPCs to successfully IVD regeneration. Because IVDSPCs can be extracted from patients with disc herniation avoiding additional damage, the IVDSPCs are more accessible than other types of stem/progenitor cells.

However, few studies have reported the biological properties of the IVDSPCs in detail and their potential application, limiting our knowledge about these cells. In particular, the current understanding of IVDSPCs is mainly based on in vitro experiments, which may differ in vivo. IVDSPC properties are still controversial depending on the type of cell (NPSPCs, AFSPCs, and CEPSPCs). Therefore, further studies should focus on the accurate identification of the IVDSPC properties in vivo based on new technologies and animal models. Preclinical studies are required for improving the therapeutic effect of the IVDSPCs for clinical translation. Future studies should also focus on improving the endogenous repair of IVD based on endogenous IVDSPCs to promote IVDSPC migration to damaged IVD tissues and improve the activity and viability of the IVDSPCs. More compatible biomaterials should be developed to load the IVDSPCs into the degenerated IVD for cell-based transplantation. Because cell-free therapies can circumvent obstacles caused by traditional cell-based therapies, the IVDSPC-derived factors, such as EVs, are also powerful therapeutic agents for IVDD. Overall, IVDSPCs are a promising cell “seed” for IVD regeneration.

Conflicts of Interest

All authors state that they have no conflicts of interest to report.

Authors’ Contributions

Zhang LL gave the brief introduction of this article. Du YX, Wang ZK, and Wu YM were responsible for manuscript writing. Liu CY and Zhang LL revised the manuscript. All authors approved the final version of this manuscript. Lingli Zhang and Chengyi Liu contributed equally to this work.
Acknowledgments

We appreciate the time and effort of the participants in this study. The work was supported by the Youth Program of National Natural Science Foundation of China (81902298) and China Postdoctoral Science Foundation funded project (2021T140224).

References

[1] Y. Zhang, Y. Hu, W. Wang et al., “Current progress in the Endogenous Repair of Intervertebral Disk Degeneration Based on Progenitor Cells,” Frontiers in bioengineering and biotechnology, vol. 8, p. 629088, 2021.
[2] N. M. Paige, I. M. Miake-Lye, M. S. Booth et al., “Association of spinal manipulative therapy with clinical benefit and harm for acute low back pain: systematic review and meta-analysis,” JAMA, vol. 317, no. 14, pp. 1451–1460, 2017.
[3] A. Maetzel and L. Li, “The economic burden of low back pain: a review of studies published between 1996 and 2001,” Best Practice & Research. Clinical Rheumatology, vol. 16, no. 1, pp. 23–30, 2002.
[4] D. Borenstein, “Mechanical low back pain—a rheumatologist’s view,” Nature reviews. Rheumatology, vol. 9, no. 11, pp. 643–653, 2013.
[5] D. Sakai and S. Grad, “Advancing the cellular and molecular therapy for intervertebral disc disease,” Advanced Drug Delivery Reviews, vol. 84, pp. 159–171, 2015.
[6] F. Wang, Z. X. Gao, F. Cai et al., “Formation, function, and exhaustion of notochordal cytoplasmic vacuoles within intervertebral disc: current understanding and speculation,” Oncotarget, vol. 8, no. 34, pp. 57800–57812, 2017.
[7] J. Cassidy, A. Hiltner, and E. Baer, “Hierarchical structure of the intervertebral disc,” Connective Tissue Research, vol. 23, no. 1, pp. 75–88, 1989.
[8] B. Wang, W. Ke, K. Wang et al., “Mechanosensitive ion channel Piezo1 activated by matrix stiffness regulates oxidative stress-induced senescence and apoptosis in human intervertebral disc degeneration,” Oxidative Medicine and Cellular Longevity, vol. 2021, 8884913 pages, 2021.
[9] K. Zhang, C. Xue, N. Lu et al., “Mechanical loading mediates human nucleus pulposus cell viability and extracellular matrix metabolism by activating of NF-kB,” Experimental and Therapeutic Medicine, vol. 18, pp. 1587–1594, 2019.
[10] L. J. Smith, N. L. Nerurkar, K. S. Choi, B. D. Harfe, and D. M. Elliott, “Degeneration and regeneration of the intervertebral disc: lessons from development,” Disease Models & Mechanisms, vol. 4, no. 1, pp. 31–41, 2011.
[11] L. Frapin et al., “Lessons learned from intervertebral disc pathophysiology to guide rational design of sequential delivery systems for therapeutic biological factors,” Advanced Drug Delivery Reviews, vol. 149-150, pp. 49–71, 2019.
[12] J. P. Urban and S. Roberts, “Degeneration of the intervertebral disc,” Arthritis Research & Therapy, vol. 5, pp. 120–130, 2003.
[13] J. L. Bron, M. N. Helder, H. J. Meisel, B. J. Van Royen, and T. H. Smit, “Repair, regenerative and supportive therapies of the annulus fibrosus: achievements and challenges,” European Spine Journal, vol. 18, no. 3, pp. 301–313, 2009.
[14] B. Chen et al., “Surgical versus non-operative treatment for lumbar disc herniation: a systematic review and meta-analysis,” Clinical Rehabilitation, vol. 32, no. 2, pp. 146–160, 2018.
[15] J. Clouet, M. Fusellier, A. Camus, C. Le Visage, and J. Guiccheux, “Intervertebral disc regeneration: from cell therapy to the development of novel bioinspired endogenous repair strategies,” Advanced Drug Delivery Reviews, vol. 146, pp. 306–324, 2019.
[16] W. Wang, Y. Wang, G. Deng et al., “Transplantation of hypoxic-preconditioned bone mesenchymal stem cells retards intervertebral disc degeneration via enhancing implanted cell survival and migration in rats,” Stem Cells International, vol. 2018, 7564113 pages, 2018.
[17] D. Sheyn, S. Ben-David, W. Tawackoli et al., “Human iPSCs can be differentiated into notochordal cells that reduce intervertebral disc degeneration in a porcine model,” Theranostics, vol. 9, no. 25, pp. 7506–7524, 2019.
[18] N. Kregar Velikonja, J. Urban, M. Fröhlich et al., “Cell sources for nucleus pulposus regeneration,” European Spine Journal, vol. 23, Suppl 3, pp. 364–374, 2014.
[19] I. Urits, A. Capuco, M. Sharma et al., “Stem cell therapies for treatment of discogenic low back pain: a comprehensive review,” Current Pain and Headache Reports, vol. 23, no. 9, p. 65, 2019.
[20] D. Sakai and G. B. Andersson, “Stem cell therapy for intervertebral disc regeneration: obstacles and solutions,” Nature Reviews Rheumatology, vol. 11, no. 4, pp. 243–256, 2015.
[21] A. Binch, J. Fitzgerald, E. Growney, and F. Barry, “Cell-based strategies for IVD repair: clinical progress and translational obstacles,” Nature reviews. Rheumatology, vol. 17, no. 3, pp. 158–175, 2021.
[22] K. Ma, S. Chen, Z. Li et al., “Mechanisms of endogenous repair failure during intervertebral disc degeneration,” Osteoarthritis and Cartilage, vol. 27, no. 1, pp. 41–48, 2019.
[23] D. Sakai, Y. Nakamura, T. Nakai et al., “Exhaustion of nucleus pulposus progenitor cells with ageing and degeneration of the intervertebral disc,” Nature Communications, vol. 3, no. 1, p. 1264, 2012.
[24] F. J. Lyu, K. M. Cheung, Z. Zheng, H. Wang, D. Sakai, and V. Y. Leung, “IVD progenitor cells: a new horizon for understanding disc homeostasis and repair,” Nature Reviews Rheumatology, vol. 15, no. 2, pp. 102–112, 2019.
[25] Q. Shen, L. Zhang, B. Chai, and X. Ma, “Isolation and characterization of mesenchymal stem-like cells from human nucleus pulposus tissue,” Science China. Life Sciences, vol. 58, pp. 509–511, 2015.
[26] B. Hu, R. He, K. Ma et al., “Intervertebral disc-derived stem/progenitor cells as a promising cell source for intervertebral disc regeneration,” Stem Cells International, vol. 2018, 11 pages, 2018.
[27] S. Mirza and A. White, “Anatomy of intervertebral disc and pathophysiology of herniated disc disease,” Journal of Clinical Laser Medicine & Surgery, vol. 13, no. 3, pp. 131–142, 1995.
[28] B. R. Whatley and X. Wen, “Intervertebral disc (IVD): structure, degeneration, repair and regeneration,” Materials Science and Engineering: C, vol. 32, no. 2, pp. 61–77, 2012.
[29] J. Chen, W. Yan, and L. A. Setton, “Molecular phenotypes of notochordal cells purified from immature nucleus pulposus,” European Spine Journal, vol. 15, Suppl 3, pp. 303–311, 2006.
[30] J. Trout, J. Buckwalter, and K. Moore, “Ultrastructure of the human intervertebral disc: II. Cells of the nucleus pulposus,” Cells of the nucleus pulposus. The Anatomical record, vol. 204, no. 4, pp. 307–314, 1982.
[31] J. Trout, J. Buckwalter, K. Moore, and S. Landas, “Ultrastructural features of the human intervertebral disc. I. Changes in notochordal cells with age,” I. Changes in notochordal cells with age. Tissue & cell, vol. 14, no. 2, pp. 359–369, 1982.

[32] J. Urban and J. McMullin, “Swelling pressure of the intervertebral disc: influence of proteoglycan and collagen contents,” Biochemistry, vol. 22, no. 2, pp. 145–157, 1985.

[33] G. Vadala, F. Russo, L. Ambrosio, M. Loppini, and P. Raj, “The potential stem cell niche in the intervertebral disc region, World J Stem Cells, vol. 8, pp. 185–201, 2016.

[34] P. Raj, “Intervertebral disc: anatomy-physiology-pathophysiology-treatment,” Pain practice: the official journal of World Institute of Pain, vol. 8, no. 1, pp. 18–44, 2008.

[35] S. Bruehlmann, J. Rattner, J. Matyas, and N. Duncan, “Regional variations in the cellular matrix of the annulus fibrosus of the intervertebral disc,” Journal of Anatomy, vol. 201, pp. 159–171, 2002.

[36] G. Fontana, E. See, and A. Pandit, “Current trends in biologics delivery to restore intervertebral disc anabolism,” Advanced Drug Delivery Reviews, vol. 84, pp. 146–158, 2015.

[37] J. C. Lotz, A. J. Fields, and E. C. Liebenberg, “The role of the vertebral end plate in low back pain,” Global Spine Journal, vol. 3, pp. 153–164, 2013.

[38] T. Grunhagen, A. Shirazi-Adl, J. Fairbank, and J. Urban, “Intervertebral disc nutrition: a review of factors influencing concentrations of nutrients and metabolites,” The Orthopedic clinics of North America, vol. 42, no. 4, pp. 465–477, 2011.

[39] M. Risbud, A. Guttapalli, T. T. Tsai et al., “Evidence for skeletal progenitor cells in the degenerate human intervertebral disc,” Spine, vol. 32, no. 23, pp. 2537–2544, 2007.

[40] H. B. Henriksson, M. Thornemo, C. Karlsson et al., “Identification of cell proliferation zones, progenitor cells and a potential stem cell niche in the intervertebral disc region,” spine, vol. 34, no. 21, pp. 2278–2287, 2009.

[41] H. B. Henriksson, E. Svala, E. Skoildbrand, A. Lindahl, and H. Brisby, “Support of concept that migrating progenitor cells from stem cell niches contribute to normal regeneration of the adult mammal intervertebral disc: a descriptive study in the New Zealand white rabbit,” Spine (Phila Pa 1976), vol. 37, no. 9, pp. 722–732, 2012.

[42] W. M. Erwin, D. Islam, E. Effekarpour, R. D. Inman, M. Z. Karim, and M. G. Fehlings, “Intervertebral disc-derived stem cells: implications for regenerative medicine and neural repair,” Spine (Phila Pa 1976), vol. 38, no. 3, pp. 211–216, 2013.

[43] K.-W. Kim, T. H. Lim, J. G. Kim, S. T. Jeong, K. Masuda, and H. S. An, “The origin of chondrocytes in the nucleus pulposus and histologic findings associated with the transition of a notochordal nucleus pulposus to a fibrocartilaginous nucleus pulposus in intact rabbit intervertebral discs,” Spine (Phila Pa 1976), vol. 28, no. 10, pp. 982–990, 2003.

[44] K.-W. Kim, K. Y. Ha, J. S. Lee et al., “Notochordal cells stimulate migration of cartilage end plate chondrocytes of the intervertebral disc in in vitro cell migration assays,” The Spine Journal, vol. 9, no. 4, pp. 323–329, 2009.

[45] L. T. Liu, B. Huang, C. Q. Li, Y. Zhuang, J. Wang, and Y. Zhou, “Characteristics of stem cells derived from the degenerated human intervertebral disc cartilage endplate,” PLoS One, vol. 6, no. 10, article e26285, 2011.

[46] C. J. Xiong, B. Huang, Y. Zhou et al., “Macrophage migration inhibitory factor inhibits the migration of cartilage end plate-derived stem cells by reacting with CD74,” PLoS One, vol. 7, no. 8, article e39384, 2012.

[47] R. Shi, F. Wang, X. Hong et al., “The presence of stem cells in potential stem cell niches of the intervertebral disc region: an in vitro study on rats,” European Spine Journal, vol. 24, no. 11, pp. 2411–2424, 2015.

[48] Z. Li, S. Chen, K. Ma et al., “Comparison of different methods for the isolation and purification of rat nucleus pulposus-derived mesenchymal stem cells,” Connective Tissue Research, vol. 61, no. 5, pp. 426–434, 2020.

[49] C. Liu, Q. Guo, J. Li et al., “Identification of rabbit annulus fibrosus-derived stem cells,” PLoS One, vol. 9, no. 9, article e108239, 2014.

[50] B. Huang, L. T. Liu, C. Q. Li et al., “Study to determine the presence of progenitor cells in the degenerated human cartilage endplates,” European Spine Journal, vol. 21, no. 4, pp. 613–622, 2012.

[51] A. Barzegar Behrooz, A. Syahir, and S. Ahmad, “CD133: beyond a cancer stem cell biomarker,” Journal of Drug Targeting, vol. 27, no. 3, pp. 257–269, 2019.

[52] T. Kloskowsk¡, J. Jarzabkowska, A. Jundzill et al., “CD133 antigen as a potential marker of melanoma stem cells: in vitro and in vivo studies,” Stem Cells International, vol. 2020, 8810410 pages, 2020.

[53] S. E. Navone, G. Marfa, L. Canzi et al., “Expression of neural and neurotrophic markers in nucleus pulposus cells isolated from degenerated intervertebral disc,” Journal of Orthopaedic Research, vol. 30, no. 9, pp. 1470–1477, 2012.

[54] H. Zhang, X. Ma, L. Zhang, X. Guan, T. Bai, and C. Xue, “The ability to form cartilage of NPMSG and BMSC in SD rats,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 4, pp. 4989–4996, 2015.

[55] H. Wu, X. Zeng, J. Yu et al., “Comparison of nucleus pulposus stem/progenitor cells isolated from degenerated intervertebral discs with umbilical cord derived mesenchymal stem cells,” Experimental Cell Research, vol. 361, no. 2, pp. 324–332, 2017.

[56] H. Li, Y. Tao, C. Liang et al., “Influence of hypoxia in the intervertebral disc on the biological behaviors of rat adipose and nucleus pulposus-derived mesenchymal stem cells,” Cells, Tissues, Organs, vol. 198, no. 4, pp. 266–277, 2013.

[57] B. Han, H. C. Wang, H. Li et al., “Nucleus pulposus mesenchymal stem cells in acidic conditions mimicking degenerative intervertebral discs give better performance than adipose tissue-derived mesenchymal stem cells,” Cells, Tissues, Organs, vol. 199, no. 5–6, pp. 342–352, 2015.

[58] L. Ni, X. Liu, K. R. Sochacki et al., “Effects of hypoxia on differentiation from human placenta-derived mesenchymal stem cells to nucleus pulposus-like cells,” The Spine Journal, vol. 14, no. 10, pp. 2451–2458, 2014.

[59] X. B. Han, Y. L. Zhang, H. Y. Li et al., “Differentiation of human ligamentum flavum stem cells toward nucleus pulposus-like cells induced by coculture system and hypoxia,” Spine, vol. 40, no. 12, pp. E665–E674, 2015.

[60] J. Wang, Y. Tao, X. Zhou et al., “The potential of chondrogenic pre-differentiation of adipose-derived mesenchymal stem cells for regeneration in harsh nucleus pulposus microenvironment,” Experimental Biology and Medicine (Maywood, N.J.), vol. 241, no. 18, pp. 2104–2111, 2016.

[61] L. Liang, X. Li, D. Li et al., “The characteristics of stem cells in human degenerative intervertebral disc,” Medicine (Baltimore), vol. 96, no. 25, p. e7178, 2017.
CCLS/RANTE5 is a key chemoattractant released by degenerative intervertebral discs in organ culture," European cells & materials, vol. 27, pp. 124–136, 2014.

J. Ying, Z. Han, S. Pei, L. Su, and D. Ruan, "Effects of stromal cell-derived factor-1α secreted in degenerative intervertebral disc on activation and recruitment of nucleus pulposus-derived stem cells," Stem Cells International, vol. 2019, 9147814 pages, 2019.

C. Pereira, R. M. Gonçalves, M. Peroglio et al., "The effect of hyaluronan-based delivery of stromal cell-derived factor-1 on the recruitment of MSCs in degenerating intervertebral discs," Biomaterials, vol. 35, no. 28, pp. 8144–8153, 2014.

L. Frapin, J. Clouet, C. Chèdeville et al., "Controlled release of biological factors for endogenous progenitor cell migration and intervertebral disc extracellular matrix remodelling," Biomaterials, vol. 253, p. 120107, 2020.

Y. Liu, J. Lin, X. Wu et al., "Aspirin-mediated attenuation of intervertebral disc degeneration by ameliorating reactive oxygen species in vivo and in vitro," Oxidative Medicine and Cellular Longevity, vol. 2019, 7189820 pages, 2019.

Y. Zhang et al., "Melatonin modulates IL-1β-induced extracellular matrix remodeling in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration and inflammation," Aging, vol. 11, pp. 10499–10512, 2019.

J. Wang, Y. Huang, L. Huang et al., "Novel biomarkers of intervertebral disc cells and evidence of stem cells in the intervertebral disc," Osteoarthritis and Cartilage, vol. 29, no. 3, pp. 389–401, 2021.

I. L. Mohd Isa, S. A. Abbah, M. Kilcoyne et al., "Implantation of hyaluronic acid hydrogel prevents the pain phenotype in a rat model of intervertebral disc injury," Science Advances, vol. 4, no. 4, p. eaax0597, 2018.

W. Chen, H. Chen, D. Zheng et al., "Gene-hydrgel microenvironment regulates extracellular matrix metabolism balance in nucleus pulposus," Adv Sci (Weinh), vol. 7, no. 1, p. 1902099, 2020.

A. S. Croft, S. Illien-Jünger, S. Grad, J. Guerrero, S. Wangler, and B. Gantenbein, "The application of mesenchymal stromal cells and their homing capabilities to regenerate the intervertebral disc," International journal of molecular sciences, vol. 22, no. 7, p. 3519, 2021.

N. Piazza, M. Dehghani, T. R. Gaborski, and K. Wuertz-Kozak, "Therapeutic potential of extracellular vesicles in degenerative diseases of the intervertebral disc," Frontiers in Bioengineering and Biotechnology, vol. 8, p. 311, 2020.

S. Rani, A. Ryan, M. Griffin, and T. Ritter, "Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications," Molecular therapy: the journal of the American Society of Gene Therapy, vol. 23, no. 5, pp. 812–823, 2015.

J. Cabral, A. E. Ryan, M. D. Griffin, and T. Ritter, "Extracellular vesicles as modulators of wound healing," Advanced Drug Delivery Reviews, vol. 129, pp. 394–406, 2018.

M. Zhao, S. Liu, C. Wang et al., "Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA," ACS Nano, vol. 15, no. 1, pp. 1519–1538, 2021.

L. Zhang, X. Y. Zhu, Y. Zhao et al., "Selective intrarenal delivery of mesenchymal stem cell-derived extracellular vesicles attenuates myocardial injury in experimental metabolic renovascular disease," Basic Research in Cardiology, vol. 115, no. 2, p. 16, 2020.

A. Eirin, X. Y. Zhu, A. S. Puranik et al., "Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation," Kidney International, vol. 92, no. 1, pp. 114–124, 2017.

Z. L. Hu, H. Y. Li, X. Chang et al., "Exosomes derived from stem cells as an emerging therapeutic strategy for intervertebral disc degeneration," World Journal of Stem Cells, vol. 12, no. 8, pp. 803–813, 2020.

X. Cheng, G. Zhang, L. Zhang et al., "Mesenchymal stem cells deliver exogenous miR-21 via exosomes to inhibit nucleus pulposus cell apoptosis and reduce intervertebral disc degeneration," Journal of Cellular and Molecular Medicine, vol. 22, no. 1, pp. 261–276, 2018.

H. Xiang, W. L. Su, X. L. Wu et al., "Exosomes derived from human urine-derived stem cells inhibit intervertebral disc degeneration by ameliorating endoplasmic reticulum stress," Oxidative Medicine and Cellular Longevity, vol. 2020, 21 pages, 2020.

Z. Liao, R. Luo, G. Li et al., "Exosomes from mesenchymal stem cells modulate endoplasmic reticulum stress to protect against nucleus pulposus cell death and ameliorate intervertebral disc degeneration in vivo," Theranostics, vol. 9, no. 14, pp. 4084–4100, 2019.

D. Hingert, K. Ekstrom, J. Aldridge, R. Crescitali, and H. Brisby, "Extracellular vesicles from human mesenchymal stem cells expedite chondrogenesis in 3D human degenerative disc cell cultures," Stem Cell Research & Therapy, vol. 11, no. 1, p. 323, 2020.

Z. Guo, W. L. Su, R. Y. Zhou et al., "Exosomal MATN3 of urine-derived stem cells ameliorates intervertebral disc degeneration by antisenseencence effects and promotes NPC proliferation and ECM synthesis by activating TGF-β," Oxidative Medicine and Cellular Longevity, vol. 2021, 18 pages, 2021.

M. Li, R. Li, S. Yang et al., "Exosomes derived from bone marrow mesenchymal stem cells prevent acidic pH-induced damage in human nucleus pulposus cells," Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, vol. 26, p. e922928, 2020.

L. Qi, R. Wang, Q. Shi, M. Yuan, M. Jin, and D. Li, "Umbilical cord mesenchymal stem cell conditioned medium restored the expression of collagen II and aggrecan in nucleus pulposus mesenchymal stem cells exposed to high glucose," Journal of Bone and Mineral Metabolism, vol. 37, no. 3, pp. 455–466, 2019.

X. Chen, L. Zhu, G. Wu, Z. Liang, L. Yang, and Z. du, "A comparison between nucleus pulposus-derived stem cell transplantation and nucleus pulposus cell transplantation for the treatment of intervertebral disc degeneration in a rabbit model," International Journal of Surgery, vol. 28, pp. 77–82, 2016.

J. Blanco, I. F. Graciani, F. M. Sanchez-Guijo et al., "Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus," Spine, vol. 35, no. 26, pp. 2259–2265, 2010.

X. C. Li, Y. Tang, J. H. Wu, P. S. Yang, D. L. Wang, and D. K. Ruan, "Characteristics and potentials of stem cells derived from human degenerated nucleus pulposus: potential for regeneration of the intervertebral disc," BMC Musculoskeletal Disorders, vol. 18, no. 1, p. 242, 2017.

Y. Zhao, Z. Jia, S. Huang et al., "Age-related changes in nucleus pulposus mesenchymal stem cells: an in vitro study in rats," Stem Cells International, vol. 2017, 6761513 pages, 2017.
[120] S. Huang, V. Y. L. Leung, D. Long et al., "Coupling of small leucine-rich proteoglycans to hypoxic survival of a progenitor cell-like subpopulation in rhesus macaque intervertebral disc," *Biomaterials*, vol. 34, no. 28, pp. 6548–6558, 2013.

[121] M. Yasen, Q. Fei, W. C. Hutton et al., "Changes of number of cells expressing proliferation and progenitor cell markers with age in rabbit intervertebral discs," *Acta Biochim Biophys Sin (Shanghai)*, vol. 45, no. 5, pp. 368–376, 2013.

[122] G. Feng et al., "Multipotential differentiation of human annulus fibrosus cells: an in vitro study," *The Journal of Bone and Joint Surgery-American Volume*, vol. 92, pp. 675–685, 2010.

[123] H. E. Gruber, F. E. Riley, G. L. Hoelscher, J. A. Ingram, L. Bullock, and E. N. Hanley Jr., "Human annulus progenitor cells: analyses of this viable endogenous cell population," *Journal of Orthopaedic Research*, vol. 34, no. 8, pp. 1351–1360, 2016.

[124] Q. Guo, P. Zhou, and B. Li, "Identification and characterizations of annulus fibrosus-derived stem cells," *Methods in Molecular Biology*, pp. 207–216, 1842.

[125] Y. Liu, M. N. Rahaman, and B. S. Bal, "Modulating notochordal differentiation of human induced pluripotent stem cells using natural nucleus pulposus tissue matrix," *PLoS One*, vol. 9, article e100885, 2014.

[126] C. Yuan, L. Pu, Z. He, and J. Wang, "BNIP3/Bcl-2-mediated apoptosis induced by cyclic tensile stretch in human cartilage endplate-derived stem cells," *Experimental and Therapeutic Medicine*, vol. 15, pp. 235–241, 2017.

[127] Y. Yao, Q. Deng, W. Song et al., "MIF plays a key role in regulating tissue-specific chondro-osteogenic differentiation fate of human cartilage endplate stem cells under hypoxia," *Stem Cell Reports*, vol. 7, no. 2, pp. 249–262, 2016.